GLP-1 for Teens: Safety, Guidelines & What Parents Should Know (2026)

Quick answer: Can teens take GLP-1 medications?

Yes. Wegovy (semaglutide) is FDA-approved for chronic weight management in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex). The approval was based on the STEP TEENS clinical trial, which showed an average 16% reduction in BMI over 68 weeks. GLP-1 medications for teens should always be prescribed by a pediatric provider, used alongside lifestyle modification, and monitored closely for side effects.

If your teen may benefit from GLP-1 treatment, check eligibility with a licensed provider.

FDA approval for adolescent GLP-1 use

In December 2022, the FDA expanded the approval of Wegovy (semaglutide 2.4 mg) to include adolescents aged 12 years and older with obesity (initial BMI at the 95th percentile or higher for age and sex). This was based on the STEP TEENS trial, the first major clinical trial of a GLP-1 medication in adolescents.

Other GLP-1 medications (Zepbound, Foundayo) are currently approved only for adults aged 18+. Consult your pediatric provider about which medications are available for adolescents.

The STEP TEENS trial

The STEP TEENS trial was a 68-week, double-blind, randomized controlled trial that enrolled 201 adolescents aged 12-17 with obesity. Key findings:

• 16.1% reduction in BMI in the semaglutide group vs 0.6% in the placebo group
• 73% of participants achieved at least 5% weight reduction
• 62% achieved at least 10% weight reduction
• Safety profile was similar to adults, with GI side effects (nausea, vomiting, diarrhea) being most common
• No new safety signals identified specific to adolescents

Eligibility criteria for teens

• Age 12 years or older
• BMI at or above the 95th percentile for age and sex (obesity)
• Some providers may consider BMI at 85th percentile+ with weight-related comorbidities (type 2 diabetes, severe insulin resistance, sleep apnea)
• No personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
• Not pregnant or planning pregnancy
• Willing to commit to lifestyle modifications alongside medication

Dosing for adolescents

Wegovy dosing for adolescents follows the same titration schedule as adults:

See our GLP-1 dosage chart for complete dosing information.

Side effects in teens

The side effect profile in adolescents is similar to adults:

• Nausea (most common, especially during titration)
• Vomiting
• Diarrhea or constipation
• Stomach pain
• Headache
• Fatigue

Most side effects are mild to moderate and improve over time. See our GLP-1 side effects guide for management strategies.

What parents should know

• GLP-1s are not a quick fix: They should be part of a comprehensive plan including diet, exercise, and behavioral support
• Long-term data is limited: While the STEP TEENS trial was positive, long-term safety data in adolescents is still being collected
• Monitor for mental health: Watch for mood changes, anxiety, or depression. See our GLP-1 mental health guide
• Nutrition is critical: Teens are still growing — ensure adequate protein, calcium, and micronutrient intake. See our GLP-1 protein guide
• Involve a pediatric specialist: GLP-1s for teens should be managed by a pediatric endocrinologist or adolescent medicine specialist, not a general telehealth provider
• Discuss family history: Personal or family history of thyroid cancer or MEN 2 is a contraindication

Alternatives for teens who don't qualify

If your teen doesn't meet GLP-1 eligibility criteria or you prefer to try lifestyle approaches first:

• Structured nutrition counseling with a registered dietitian
• Behavioral therapy for emotional eating or food-related issues
• Family-based treatment programs for adolescent obesity
• Increased physical activity and structured exercise programs
• Screening for underlying conditions (thyroid, PCOS, sleep apnea)

The bottom line

GLP-1 medications (specifically Wegovy) are FDA-approved and effective for adolescents aged 12+ with obesity. The STEP TEENS trial showed significant BMI reduction with a safety profile similar to adults. However, GLP-1s for teens should be part of a comprehensive treatment plan managed by a pediatric specialist, with close monitoring and ongoing lifestyle support. Parents should be actively involved in the decision-making process and understand both the benefits and limitations of medication treatment.